Buprenorphine, Naloxone Drug Combination
"Buprenorphine, Naloxone Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESIC with naloxone, a NARCOTIC ANTAGONIST to reduce the potential for NARCOTIC DEPENDENCE in the treatment of pain. It may also be used for OPIATE SUBSTITUTION THERAPY.
Descriptor ID |
D000069479
|
MeSH Number(s) |
D03.132.577.249.150.500 D03.132.577.249.706.275 D03.605.497.150.500 D03.605.497.750.275 D03.633.400.686.150.500 D03.633.400.686.750.275 D04.615.723.795.150.500 D04.615.723.795.706.275 D26.310.352
|
Concept/Terms |
Buprenorphine, Naloxone Drug Combination- Buprenorphine, Naloxone Drug Combination
- Buprenorphine-Naloxone Drug Combination
- Combination, Buprenorphine-Naloxone Drug
- Drug Combination, Buprenorphine-Naloxone
- Buprenorphine-Naloxone
- Buprenorphine Naloxone
- Naloxone, Buprenorphine
- Buprenorphine-Naloxone Combination
- Buprenorphine Naloxone Combination
- Combination, Buprenorphine-Naloxone
- Buprenorphine Naloxone Drug Combination
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine, Naloxone Drug Combination".
- Chemicals and Drugs [D]
- Heterocyclic Compounds [D03]
- Alkaloids [D03.132]
- Opiate Alkaloids [D03.132.577]
- Morphinans [D03.132.577.249]
- Buprenorphine [D03.132.577.249.150]
- Buprenorphine, Naloxone Drug Combination [D03.132.577.249.150.500]
- Naloxone [D03.132.577.249.706]
- Buprenorphine, Naloxone Drug Combination [D03.132.577.249.706.275]
- Heterocyclic Compounds, Bridged-Ring [D03.605]
- Morphinans [D03.605.497]
- Buprenorphine [D03.605.497.150]
- Buprenorphine, Naloxone Drug Combination [D03.605.497.150.500]
- Naloxone [D03.605.497.750]
- Buprenorphine, Naloxone Drug Combination [D03.605.497.750.275]
- Heterocyclic Compounds, Fused-Ring [D03.633]
- Heterocyclic Compounds, 4 or More Rings [D03.633.400]
- Morphinans [D03.633.400.686]
- Buprenorphine [D03.633.400.686.150]
- Buprenorphine, Naloxone Drug Combination [D03.633.400.686.150.500]
- Naloxone [D03.633.400.686.750]
- Buprenorphine, Naloxone Drug Combination [D03.633.400.686.750.275]
- Polycyclic Compounds [D04]
- Polycyclic Aromatic Hydrocarbons [D04.615]
- Phenanthrenes [D04.615.723]
- Morphinans [D04.615.723.795]
- Buprenorphine [D04.615.723.795.150]
- Buprenorphine, Naloxone Drug Combination [D04.615.723.795.150.500]
- Naloxone [D04.615.723.795.706]
- Buprenorphine, Naloxone Drug Combination [D04.615.723.795.706.275]
- Pharmaceutical Preparations [D26]
- Drug Combinations [D26.310]
- Buprenorphine, Naloxone Drug Combination [D26.310.352]
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine, Naloxone Drug Combination".
This graph shows the total number of publications written about "Buprenorphine, Naloxone Drug Combination" by people in this website by year, and whether "Buprenorphine, Naloxone Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 0 | 1 | 1 |
2018 | 2 | 0 | 2 |
2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Buprenorphine, Naloxone Drug Combination" by people in Profiles.
-
Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence. J Am Board Fam Med. 2021 Feb; 34(Suppl):S141-S146.
-
Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report. J Addict Med. 2020 Jul/Aug; 14(4):e136-e138.
-
A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder. J Rural Health. 2021 01; 37(1):169-171.
-
Factors impeding switching from methadone to buprenorphine in heroin users receiving methadone maintenance therapy - A naturalistic cohort study. J Subst Abuse Treat. 2019 10; 105:51-56.
-
Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs. Ann Intern Med. 2019 01 15; 170(2):127-128.
-
The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible. J Addict Med. 2018 Nov/Dec; 12(6):459-465.
-
Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. Int J Drug Policy. 2017 08; 46:136-145.